Teva looks set to wait until early in 2035 to launch its proposed generic version of Catalyst Pharmaceuticals’ Firdapse (amifampridine) 10mg tablets in the US, after striking a settlement agreement with the originator that resolves all litigation previously pending in a district court in New Jersey.
Teva Leapfrogs One ANDA Sponsor But Faces Decade Wait On US Firdapse Opportunity
Patent-Litigation Settlement Provides For February 2035 Entry; Two Actions Ongoing
Catalyst saw its share price jump by around 14% after striking what the market termed a favorable patent-litigation settlement agreement with ANDA sponsor Teva over its rare disease drug Firdapse.
